Revelation Biosciences Stock Probability of Future Stock Price Finishing Over 0.99

REVB Stock  USD 0.36  0.01  2.86%   
Revelation Biosciences' future price is the expected price of Revelation Biosciences instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Revelation Biosciences performance during a given time horizon utilizing its historical volatility. Check out Revelation Biosciences Backtesting, Revelation Biosciences Valuation, Revelation Biosciences Correlation, Revelation Biosciences Hype Analysis, Revelation Biosciences Volatility, Revelation Biosciences History as well as Revelation Biosciences Performance.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.
  
At present, Revelation Biosciences' Price Book Value Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Earnings To Growth Ratio is expected to grow to 0.30, whereas Price Earnings Ratio is forecasted to decline to (29.90). Please specify Revelation Biosciences' target price for which you would like Revelation Biosciences odds to be computed.

Revelation Biosciences Target Price Odds to finish over 0.99

The tendency of Revelation Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 0.99  or more in 90 days
 0.36 90 days 0.99 
about 9.12
Based on a normal probability distribution, the odds of Revelation Biosciences to move over $ 0.99  or more in 90 days from now is about 9.12 (This Revelation Biosciences probability density function shows the probability of Revelation Stock to fall within a particular range of prices over 90 days) . Probability of Revelation Biosciences price to stay between its current price of $ 0.36  and $ 0.99  at the end of the 90-day period is about 86.09 .
Given the investment horizon of 90 days Revelation Biosciences has a beta of -0.62 indicating as returns on the benchmark increase, returns on holding Revelation Biosciences are expected to decrease at a much lower rate. During a bear market, however, Revelation Biosciences is likely to outperform the market. Additionally Revelation Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Revelation Biosciences Price Density   
       Price  

Predictive Modules for Revelation Biosciences

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Revelation Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Revelation Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.020.398.93
Details
Intrinsic
Valuation
LowRealHigh
0.163.1311.67
Details
1 Analysts
Consensus
LowTargetHigh
10.4211.4512.71
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.85-0.54-0.23
Details

Revelation Biosciences Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Revelation Biosciences is not an exception. The market had few large corrections towards the Revelation Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Revelation Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Revelation Biosciences within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.7
β
Beta against Dow Jones-0.62
σ
Overall volatility
0.21
Ir
Information ratio -0.09

Revelation Biosciences Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Revelation Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Revelation Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Revelation Biosciences generated a negative expected return over the last 90 days
Revelation Biosciences has high historical volatility and very poor performance
Revelation Biosciences has some characteristics of a very speculative penny stock
Revelation Biosciences has a very high chance of going through financial distress in the upcoming years
Revelation Biosciences currently holds 5.56 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Revelation Biosciences has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Revelation Biosciences' use of debt, we should always consider it together with its cash and equity.
Net Loss for the year was (120.25 K) with profit before overhead, payroll, taxes, and interest of 90.91 M.
Revelation Biosciences currently holds about 3.48 M in cash with (7.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15.
Revelation Biosciences has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Disposition of tradable shares by Carson William Howard of Revelation Biosciences subject to Rule 16b-3

Revelation Biosciences Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Revelation Stock often depends not only on the future outlook of the current and potential Revelation Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Revelation Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding228.6 K
Cash And Short Term Investments12 M

Revelation Biosciences Technical Analysis

Revelation Biosciences' future price can be derived by breaking down and analyzing its technical indicators over time. Revelation Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Revelation Biosciences. In general, you should focus on analyzing Revelation Stock price patterns and their correlations with different microeconomic environments and drivers.

Revelation Biosciences Predictive Forecast Models

Revelation Biosciences' time-series forecasting models is one of many Revelation Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Revelation Biosciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Revelation Biosciences

Checking the ongoing alerts about Revelation Biosciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Revelation Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Revelation Biosciences generated a negative expected return over the last 90 days
Revelation Biosciences has high historical volatility and very poor performance
Revelation Biosciences has some characteristics of a very speculative penny stock
Revelation Biosciences has a very high chance of going through financial distress in the upcoming years
Revelation Biosciences currently holds 5.56 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Revelation Biosciences has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Revelation Biosciences' use of debt, we should always consider it together with its cash and equity.
Net Loss for the year was (120.25 K) with profit before overhead, payroll, taxes, and interest of 90.91 M.
Revelation Biosciences currently holds about 3.48 M in cash with (7.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15.
Revelation Biosciences has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Disposition of tradable shares by Carson William Howard of Revelation Biosciences subject to Rule 16b-3
When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(17.53)
Return On Assets
(0.51)
Return On Equity
(2.70)
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.